Friday, October 30, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 5, 2026

Samsara projects FY 2027 revenue of $2.005B-$2.013B while targeting 20% non-GAAP operating margin

View original at seekingalpha.com
Samsara projects FY 2027 revenue of $2.005B-$2.013B while targeting 20% non-GAAP operating margin Earnings Call Insights: Samsara (IOT) Q1 fiscal 2027 MANAGEMENT VIEW * "Samsara delivered a strong start to FY '27, with another quarter of durable and efficient growth" (CEO Sanjit Biswas), including: "We ended Q1 with ne…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • In Q1, Samsara added 169 customers with $100,000+ ARR and 15 customers with $1 million+ ARR

    60% confidence
  • The Hertz deal covers approximately 0.5 million vehicles

    60% confidence
  • Samsara has confidence it will be able to find the supply it needs

    60% confidence
  • FY2027 non-GAAP operating margin expected to be 20%

    60% confidence
  • Customer expansions are more driven by more assets or licenses on the same product

    60% confidence
  • Waste Intelligence is monetized as additional SKUs

    60% confidence
  • Samsara expects to be GAAP profitable for Q2

    60% confidence
  • Q1 strength was driven by strength in emerging products

    60% confidence
  • Non-GTM functions may be roughly the same size, if not smaller

    60% confidence
  • At some point Samsara may offer a consumption-based pricing model for agents

    60% confidence
  • Q1 was Samsara's third consecutive quarter of GAAP profitability

    60% confidence
  • Ground Intelligence is priced on a per mile basis

    60% confidence
  • Q1 was another quarter of accelerating growth and improved operating leverage

    60% confidence
  • Revenue grew 31% year-over-year in Q1

    60% confidence
  • Samsara raised the full-year non-GAAP operating margin target from 19% to 20%

    60% confidence
  • 96% of $100,000-plus ARR customers subscribe to two or more products

    60% confidence
  • For Q2, Samsara expects revenue between $482 million and $484 million

    60% confidence
  • Q1 net new ARR was $101 million

    60% confidence
  • Samsara added $101 million in net new ARR in Q1

    60% confidence
  • There are no changes to hiring plans discussed on the last earnings call

    60% confidence
  • GAAP EPS would still be positive excluding the Motive arbitration award

    60% confidence
  • Nothing about Q1 strength stands out as one-time in nature

    60% confidence
  • Free cash flow margin was 15%

    60% confidence
  • Europe contributed a record amount of net new ACV mix

    60% confidence
  • Samsara's guidance philosophy remains the same and is de-risked for potential downside scenarios

    60% confidence
  • The Supreme Court ruling is good for Samsara's business overall

    60% confidence
  • Samsara is expanding into maintenance, training, qualifications, and workflows

    60% confidence
  • GAAP EPS was a positive $0.08

    60% confidence
  • Samsara is spending more money on AI and cloud, pressuring gross margin

    60% confidence
  • Large customers see an opportunity to bring workflows together on one platform

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com
Samsara projects FY 2027 revenue of $2.005B-$2.013B while targeting 20% non-GAAP operating margin — Source | Via News | Finance Via News